ClinicalTrials.gg
CompletedNCT06530966Updated Apr 14, 2026

Phase I Study of ICP-332 in Healthy Subjects

A Phase 1 interventional study of ICP-332 Tablets and ICP-332 Placebo Tablets in Healthy Subjects, sponsored by InnoCare Pharma Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-14.

Sponsored by InnoCare Pharma Inc. · Phase 1, Interventional, and Other

From the registry’s dates

  • Primary completion was Nov 2024, 2 years ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

A multiple ascending dose phase I study of ICP-332 in healthy subjects

02

Conditions studied

  • Healthy Subjects
03

In context

Lead sponsor

InnoCare Pharma Inc. is the lead sponsor of 5 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntarily sign the form
  2. (BMI) of ≥ 18.5 kg/m2 and \< 30 kg/m2
  3. Male or infertile female subjects who are between 18-55 years old (inclusive)

Exclusion criteria

Exclusion Criteria:

  1. Significant current or past acute or chronic disease or condition.
  2. A history of tuberculosis or current active/latent infection.
  3. With a history of drug or food allergy, or allergy to any of the composition components of the study drug, or allergic disease.
  4. Subjects with abnormalities in the screening examinations.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    ICP-332

    Drug: ICP-332 Tablets

  • Placebo comparator
    Placebo

    Drug: ICP-332 Placebo Tablets

Interventions

  • Eligible patients will receive ICP-332 tablets orally as per the protocol

  • DrugICP-332 Placebo Tablets

    Eligible patients will receive ICP-332 placebo tablets orally as per the protocol

06

What researchers measure

Primary outcomes

  1. Number of participants with Adverse Events (AEs)

    Time frame: Up to Day 28

  2. Number of Participants With Clinically Significant Change in Vital Signs

    Time frame: Up to Day 28

  3. Number of Participants With Clinically Significant Change in Electrocardiogram (ECG)

    Time frame: Up to Day 28

  4. Number of Participants With Clinically Significant Change in Physical Examination

    Time frame: Up to Day 28

  5. Number of Participants With Clinically Significant Change in Clinical Laboratory Values

    Time frame: Up to Day 28

07

Study locations

1 site
  • Pharmaron CPC Inc.
    Baltimore, Maryland 21201, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2024 to primary completion in Nov 2024, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 28, 2024
First posted
Jul 31, 2024
StartActual
Jul 23, 2024
Primary completionActual
Nov 8, 2024
CompletionActual
Nov 8, 2024
Last update
Apr 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06530966
Responsible party
Sponsor
First posted
Jul 31, 2024
Start date
Jul 23, 2024
Primary completion
Nov 8, 2024
Completion
Nov 8, 2024
Last update
Apr 14, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ICP-332

Start the discussion